Home » Stocks » Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc. (CNST)

Stock Price: $28.98 USD 0.15 (0.52%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.38B
Revenue (ttm) n/a
Net Income (ttm) -91.57M
Shares Out 41.99M
EPS (ttm) -2.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $28.98
Previous Close $28.83
Change ($) 0.15
Change (%) 0.52%
Day's Open 29.15
Day's Range 28.17 - 29.55
Day's Volume 558,076
52-Week Range 6.01 - 59.49

More Stats

Market Cap 1.38B
Enterprise Value 1.06B
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 41.99M
Float 29.39M
EPS (basic) -2.89
EPS (diluted) -2.85
FCF / Share -1.93
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.02M
Short Ratio 3.22
Short % of Float 7.49%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.17
Revenue n/a
Operating Income -91.93M
Net Income -91.57M
Free Cash Flow -80.45M
Net Cash 318.83M
Net Cash / Share 6.71
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -23.08%
ROE -45.60%
ROIC -86.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 7
Overweight 1
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(83.64% upside)
Current: 28.98
Target: 53.22
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-86.06-61.24-39.09-33.66
Net Income-85.55-59.93-35.38-34.53
Shares Outstanding28.1511.980.960.93
Earnings Per Share-3.04-5.00-56.10-53.19
Operating Cash Flow-72.25-48.82-37.59-32.78
Capital Expenditures-0.70-0.48-0.58-0.95
Free Cash Flow-72.95-49.30-38.17-33.72
Cash & Equivalents38411516.6537.16
Total Debt40.96-4.1010.64
Net Cash / Debt34311512.5426.52
Book Value338104-166-132
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Constellation Pharmaceuticals, Inc.
Country United States
Employees 106
CEO Jigar Raythatha

Stock Information

Ticker Symbol CNST
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CNST
IPO Date July 19, 2018


Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.